More researchers continue to assess the prognostic role of serum GGT in cervical cancer (43), esophageal squamous cell carcinoma (44), ovarian cancer (45), renal cell carcinoma (25), and HCC (46). This evidence concerns the gene GGT1 and cervical carcinoma.